Inventurus Knowledge Solutions Limited — PPTs, 03-07-2025: Investor Presentation

1. Financial Highlights:

No standalone financial results or specific revenue/profit figures disclosed in this presentation. However, the partnership with Western Washington Medical Group (WWMG) involves an initial $17M investment into the MSO, indicating capital deployment aimed at growth via operational and clinical efficiencies.

2. Strategic Initiatives & Growth Drivers:

IKS is transitioning from a platform provider to a transformation partner (IKS 3.0), offering integrated capital, capacity, and capability solutions that take ownership of outcomes in healthcare organizations. The investment in WWMG’s MSO aims to scale physician group operations, improve revenue cycle, clinical documentation, and value-based care capabilities, driving growth through organic physician additions and enhanced risk contract management.

3. Business Developments:

IKS is making a strategic investment in WWMG, a multi-specialty physician group with $91M annual patient revenue, over 90 clinicians, and 20 specialties. An MSO structure will manage non-clinical operations, with IKS holding 48% share in the MSO and capturing a significant portion of EBITDA improvements. This model serves as a proof-point for IKS 3.0, enabling deeper partnership and aligned incentives with physician groups.

4. Market Position & Competitive Advantage:

IKS differentiates by delivering clinically validated technology combined with globalized human capital, enabling better care quality, lower operating costs, and more proactive disease management. The shift towards full transformation partnerships enhances customer stickiness and builds a sustainable moat against commoditized solutions and platform competitors.

5. Investor Implications:

This strategic move positions IKS for positive growth potential by extending its value chain and creating multiple revenue streams from platform services and equity in medical group growth. Execution risks include managing capital deployment and successful clinical-administrative integration, but the proven track record of investments and strong fundamentals lend confidence to long-term value creation.